Please assess the completion status of the following clinical trial:

Trial Title: Total Hip Arthroplasty (THA) Lumbar Plexus Verses Periarticular

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients with an American Society of Anesthesiologists (ASA) physiological status I-III~2. Patients presenting for unilateral primary total hip arthroplasty~3. Patients 18 years of age and older~Exclusion Criteria:~1. Chronic pain syndromes such as fibromyalgia or complex regional pain syndrome~2. History of long term use of daily opioids (\>1 months) with Oral Morphine Equivalent (OME) \>5mg/day~3. Body mass index (BMI) \> 40 kg/m2~4. Allergies to medications used in this study such as: fentanyl,hydromorphone, ketorolac, ibuprofen, acetaminophen, local anesthetics, oxycodone, tramadol, ondansetron, droperidol, dexamethasone, celecoxib and OxyContin~5. Major systemic medical problems such as:~   1. severe renal disorder defined as glomerular filtration rate (GFR) \<50 units/m2~  2. cardiovascular disorders defined as Congestive Heart Failure (CHF) New York Heart Association (NYHA) class III-IV~  3. severe hepatic disorder defined as current or past diagnosis of acute/subacute necrosis of liver, acute hepatic failure, chronic liver disease, cirrhosis (primary biliary cirrhosis), fatty liver, chronic hepatitis/toxic hepatitis, liver abscess, hepatic coma, hepatorenal syndrome, other disorders of liver~6. Impaired cognitive function or inability to understand the study protocol~7. Contraindication to a regional anesthesia technique (e.g., preexisting neuropathy in the operative extremity, coagulopathy \[platelets \< 100,000, International Normalized Ratio (INR) \>1.5\], refusal, etc.).~8. Previous contralateral hip replacement managed with regional or periarticular injection~9. Unable to follow-up at the 3 month interval at Mayo Clinic in Rochester, Minnesota~10. Pregnancy or breastfeeding (women of child-bearing potential will require a negative pregnancy test)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PNB Bupivacaine (Type: ACTIVE_COMPARATOR): Bupivacaine 0.5% with 1:200,000 epinephrine 30 ml bolus preoperatively followed by an infusion of bupivacaine 0.2% on post anesthesia care unit (PACU) arrival.
- PAI Ropivacaine (Type: ACTIVE_COMPARATOR): Patients 50 to 74.9 kg: ropivacaine 200 mg, epinephrine 100 ug, ketorolac 30 mg. Patients 75 to 99.9 kg: ropivacaine 300 mg, epinephrine 200 ug, ketorolac 30 mg. Patients 100 to 125 kg: ropivacaine 400 mg, epinephrine 300 ug, ketorolac 30mg.
- PAI liposomal bupivacaine (Type: ACTIVE_COMPARATOR): Liposomal bupivacaine 255 mg, ketorolac 30 mg, bupivacaine 125 mg, epinephrine 125 ug.

Based on this trial design, predict the completion outcome and termination type (if applicable).